Augmentation therapy for alpha-1 antitrypsin deficiency: Towards a personalised approach

Orphanet Journal of Rare Diseases

Volumn 8, Issue 1, 2013, Pages

  Stockley, Robert A ^a   Miravitlles, Marc ^b   Vogelmeier, Claus ^c  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Alpha 1 antitrypsin deficiency; Augmentation therapy; COPD; Risk factors

Indexed keywords

ALPHA 1 ANTITRYPSIN; BIOLOGICAL MARKER; BRONCHODILATING AGENT;

AGE; AIRWAY OBSTRUCTION; ALPHA 1 ANTITRYPSIN DEFICIENCY; AUGMENTATION THERAPY; BRONCHIECTASIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL DECISION MAKING; DISEASE COURSE; DISEASE EXACERBATION; DISEASE REGISTRY; DRUG COST; EMPHYSEMA; ENZYME THERAPY; FORCED EXPIRATORY VOLUME; HUMAN; LOCAL THERAPY; LUNG INJURY; PATIENT SELECTION; PERSONAL NEEDS; PNEUMONIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION; SPIROMETRY;

ALPHA 1-ANTITRYPSIN DEFICIENCY; DECISION MAKING; HUMANS; RISK FACTORS; SPIROMETRY;

EID: 84885015158     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/1750-1172-8-149     Document Type: Review

References (67)

1. The electrophoretic alpha-1-globulin patttern of serum in alpha-1-antitrypsin deficiency. Laurell CB, Eriksson SA, Scand J Clin Lab 1963 15 132 140
2. The induction of pulmonary emphysema with human leukocyte elastase. Senior RM, Tegner H, Kuhn C, et al. Am Rev Respir Dis 1977 116 3 469 745 900634
3. Sullivan AL, Stockley RA, Proteinases and COPD Boca Raton, Florida USA: Blackwell Publishing Ltd Chronic Obstructive Pulmonary Disease. 2007 349 366
4. Feasibility of a clinical trial of augmentation therapy for alpha-1-antitrypsin deficiency. Schluchter MD, Stoller JK, Barker AF, Buist AS, Crystal RG, Donohue JF, et al. Am J Respir Crit Care Med 2000 161 796 801 10.1164/ajrccm.161.3.9906011 10712324 (Pubitemid 30171733)
5. Collaborative study to assess risk of lung disease in Pi MZ phenotype subjects. Bruce RM, Cohen BH, Diamond EL, Fallat RJ, Knudson RJ, Lebowitz MD, et al. Am Rev Respir Dis 1984 130 386 390 6332562 (Pubitemid 14029764)
6. Biochemical efficacy and safety on monthly augmentation therapy for alpha-1-antitrypsin deficiency. Hubbard RC, Sellers S, Czerski D, Stephens L, Crystal RG, JAMA 1988 260 1259 1264 10.1001/jama.1988.03410090091037 3261353
7. Long-term variability of Desmosine/Isodesmosine as biomarker in alpha-a-antitrypsin deficiency-related COPD. Fregonese L, Ferrari F, Fumagalli M, Luisetti M, Stolk J, Iadarola P, COPD 2011 8 329 333 10.3109/15412555.2011. 589871 21793711
8. The fibrinogen cleavage product Aa-Val360, a specific marker of neutrophil elastase activity in vivo. Carter RI, Mumford RA, Treonze KM, Finke PE, Davies P, Si Q, et al. Thorax 2011 66 686 691 10.1136/thx.2010.154690 21617168
9. Survival and FEVl decline in individuals with severe deficiency of alpha-l antitrypsin. The Alpha-l-Antitrypsin Deficiency Registry Study Group, Am J Respir Crit Care Med 1998 158 49 59 9655706
10. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Seersholm N, Wencker M, Banik N, et al. Eur Respir J 1997 10 2260 2263 10.1183/09031936.97.10102260 9387950 (Pubitemid 27479546)
11. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Longitudinal follow-up of patients with alpha (1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Wencker M, Fuhrmann B, Banik N, Konietzko N, Chest 2001 119 737 744 10.1378/chest.119.3.737 11243951 (Pubitemid 32197642)
12. Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ, COPD 2009 6 177 184 10.1080/15412550902905961 19811373
13. Validation of computed tomography lung densitometry for monitoring emphysema in alpha-1 antitrypsin deficiency. Parr DG, Stoel BC, Stolk J, Stockley RA, Thorax 2006 61 485 490 10.1136/thx.2005.054890 16537666 (Pubitemid 43901517)
14. Rate of progression of lung function impairment in alpha-1 antitrypsin deficiency. Dawkins PA, Dawkins CL, Wood AM, Nightingale PG, Stockley JA, Stockley RA, Eur Respir J 2009 33 1338 1344 10.1183/09031936.00061208 19164359
15. A randomized clinical trial of alpha-1-antitrypsin augmentation therapy. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, et al. Am J Respir Crit Care Med 1999 160 1468 1472 10.1164/ajrccm.160.5.9901055 10556107
16. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA, Eur Respir J 2009 33 1345 1353 10.1183/09031936.00159408 19196813
17. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease (Review). Gøtzsche PC, Johansen HK, Cochrane Database Syst Rev 2010 7 CD007851
18. Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry. Stockley RA, Parr DG, Piitulainen E, Stolk J, Stoel BC, Dirksen A, Respir Res 2010 11 136 10.1186/1465-9921-11-136 20920370
19. Longitudinal changes in physiological, radiological, and health status measurements in alpha-1 antitrypsin deficiency and factors associated with decline. Dowson LJ, Guest PJ, Stockley RA, Am J Respir Crit Care Med 2001 164 1805 1809 10.1164/ajrccm.164.10.2106036 11734427 (Pubitemid 33152311)
20. Retinoid treatment of emphysema in patients on the Alpha-1 International Registry. The REPAIR study: study design, methodology and quality control of study assessments. Stolk J, Cooper BG, Stoel B, Rames A, Rutman O, Soliman S, Stockley R, Ther Adv Respir Dis 2010 4 319 332 10.1177/1753465810379617 20926506
21. Exploring the optimum approach to the use of CT densitometry in a randomised placebo-controlled study augmentation therapy in alpha-1-antitrypsin deficiency. Parr DG, Dirksen A, Piitulainen E, Deng C, Wencker M, Stockley RA, Respir Res 2009 10 75 10.1186/1465-9921-10-75 19678952
22. Characteristics of Italian and Spanish patients with alpha-1-antitrypsin deficiency: Identifying clinical phenotypes. Piras B, Ferrarotti I, Lara B, Martinez MT, Bustamante A, Ottaviani S, Pirina P, Luisetti M, Miravitlles M, Eur Respir J 2012 2012 in press
23. Delay in diagnosis of alpha-1 antitrypsin deficiency. A continuing problem. Stoller JK, Sandhaus RA, Turino G, Dickson R, Rodgers K, Strange C, Chest 2005 128 1989 1994 10.1378/chest.128.4.1989 16236846 (Pubitemid 41507532)
24. Diagnostic delay and clinical modifiers in alpha-1 antitrypsin deficiency. Köhlein T, Janciauskiene S, Welte T, Ther Adv Respir Dis 2010 4 279 287 10.1177/1753465810376407 20660539
25. Survival of patients with severe alpha-1 antitrypsin deficiency with special reference to non-index cases. Seersholm N, Kok-Jensen A, Dirksen A, Thorax 1994 49 695 698 10.1136/thx.49.7.695 8066566 (Pubitemid 24219149)
26. Phenotypic differences in alpha 1 antitrypsin deficient sibling pairs may relate to genetic variation. Wood AM, Needham M, Simmonds MJ, Newby PR, Gough SC, Stockley RA, Journal of COPD 2008 5 353 359 10.1080/15412550802522320
27. Liver disease in a1 antitrypsin deficiency detected by screening of 200,000 infants. Sveger T, N Engl J Med 1976 294 1316 1321 10.1056/ NEJM197606102942404 1083485
28. Inhaled corticosteroids as additional treatment in alpha-1 antitrypsin-deficiency-related COPD. Corda L, Bertella E, La Piana GE, Boni E, Redolfi S, Tantucci C, Respiration 2008 76 61 68 10.1159/000119718 18319586 (Pubitemid 351914141)
29. Determinants of airflow obstruction in severe alpha-1 antitrypsin deficiency. DeMeo D, Sandhaus RA, Barker AF, Brantly ML, Eden E, Gerard N, et al. Thorax 2007 62 805 812 (Pubitemid 47435036)
30. Development of predictive models for airflow obstruction in alpha-1 antitrypsin deficiency. Castaldi PJ, DeMeo DL, Kent DM, Campbell EJ, Barker AF, Brantly ML, et al. Am J Epidemiol 2009 170 1005 1013 10.1093/aje/kwp216 19726494
31. Risk factors for symptom onset in PI*Z alpha-1 antitrypsin deficiency. Mayer AS, Stoller JK, Ruttenber AJ, Strand M, Sandhaus RA, Newman LS, Int J Chron Obst Pulmon Dis 2007 1 485 492
32. Exacerbations in alpha-1 antitrypsin deficiency. Needham M, Stockley RA, Eur Respir J 2005 25 992 1000 10.1183/09031936.05.00074704 15929953 (Pubitemid 40823773)
33. Variability of pulmonary function in alpha-1 antitrypsin deficiency: clinical correlates. Silverman EK, Pierce JA, Province MA, Rao DC, Campbell EJ, Ann Intern Med 1989 111 982 991 10.7326/0003-4819-111-12-982 2596778 (Pubitemid 20034922)
34. The relationship of chronic sputum expectoration to physiologic, radiologic, and health status characteristics in alpha-1antitrypsin deficiency (PiZ). Dowson LJ, Guest PJ, Stockley RA, Chest 2002 122 1247 1255 10.1378/chest.122.4.1247 12377849 (Pubitemid 35339537)
35. Body mass index and mortality in patients with severe alpha-1 antitrypsin deficiency. Seersholm N, Respir Med 1997 91 77 82 10.1016/S0954-6111(97)90071-8 9122515 (Pubitemid 27107670)
36. Effect of age and occupational exposure to airway irritants on lung function in non-smoking individuals with alpha-1-antitrypsin deficiency (PiZZ). Piitulainen E, Tornling G, Eriksson S, Thorax 1997 52 244 248 10.1136/thx.52.3.244 9093340 (Pubitemid 27128174)
37. Occupational exposure risks in individuals with PI*Z alpha-1 antitrypsin deficiency. Mayer AS, Stoller JK, Bartelson BB, Ruttenber AJ, Sandhaus RA, Newman LS, Am J Respir Crit Care Med 2000 162 553 558 10.1164/ajrccm.162.2.9907117 10934086 (Pubitemid 30647199)
38. Outdoor air pollution is associated with disease severity in alpha-1 antitrypsin deficiency. Wood AM, Harrison RM, Semple S, Ayres JG, Stockley RA, Eur Respir J 2009 34 346 353 10.1183/09031936.00087908 19324958
39. Factors associated with the evolution of lung function in patients with alpha-1-antitrypsin deficiency in the Spanish Registry. Tirado-Conde G, Lara B, Casas F, Blanco I, Bustamante A, Cadenas S, Martínez MT, Lázaro L, Torres M, Hernández Pérez JM, et al. Arch Bronconeumol 2011 47 495 503 21798656
40. Clinical features and prognosis of life time non-smokers with severe alpha-1-antitrypsin deficiency. Seersholm N, Kok-Jensen A, Thorax 1998 53 265 268 10.1136/thx.53.4.265 9741368 (Pubitemid 28215785)
41. Clinical characteristics of subjects with symptoms of alpha-1 antitrypsin deficiency older than 60 years. Campos MA, Alazemi S, Zhang G, Salathe M, Wanner A, Sandhaus RA, Baier H, Chest 2009 135 600 608 10.1378/chest.08-1129 19017884
42. Airways obstruction and two year survival in patients with severe alpha 1-antitrypsin deficiency. Seersholm N, Dirksen A, Kok-Jensen A, Eur Respir J 1994 7 1985 1987 7875269 (Pubitemid 24366288)
43. Clinical course and prognosis of never-smokers with severe alpha-1 antitrypsin deficiency (PiZZ). Tanash HA, Nilsson PM, Nilsson JA, Piitulainen E, Thorax 2008 63 1091 1095 10.1136/thx.2008.095497 18682522
44. Lung function in 30-year-old alpha-1 antitrypsin deficient individuals. Bernspang E, Wollmer P, Sveger T, Piitulainen E, Respir Med 2009 103 861 865 10.1016/j.rmed.2008.12.021 19181511
45. Age related development of respiratory abnormalities in non-index α-1antitrypsin deficient studies. Holme J, Stockley JA, Stockley R, Respir Med 2013 107 387 393 10.1016/j.rmed.2012.12.003 23276486
46. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Soler-Cataluña JJ, Martinez-García MA, Roman Sánchez P, Salcedo E, Navarro M, Ochando R, Thorax 2005 60 925 931 10.1136/thx.2005.040527 16055622 (Pubitemid 41598207)
47. Alpha§ssub§1§esub§-antitrypsin and leukocyte elastase in infected and non-infected sputum. Stockley RA, Burnett D, Am Rev Respir Dis 1979 120 1081 1086 315741 (Pubitemid 10218496)
48. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha-1-antitrypsin deficiency (PiZ). Hill AT, Campbell EJ, Bayley DL, Hill SL, Stockley RA, Am J Respir Crit Care Med 1999 160 1968 1975 10.1164/ajrccm.160.6. 9904097 10588615 (Pubitemid 30004705)
49. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Lieberman J, Chest 2000 118 1480 1485 10.1378/chest.118.5.1480 11083705
50. The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency. Stockley RA, Bayley DL, Unsal I, Dowson LJ, Am J Respir Crit Care Med 2002 165 1494 1498 10.1164/rccm.2109013 12045122 (Pubitemid 34606663)
51. Serial measurements of FEV1 over 12 years in a patient with alpha-1-protease inhibitor deficiency: influence of augmentation therapy and infections. Wencker M, Denker J, Konietzko N, Respiration 1994 61 195 198 10.1159/000196336 7973103 (Pubitemid 24262449)
52. Exacerbations in subjects with alpha-1 antitrypsin deficiency receiving augmentation therapy. Campos MA, Alazemi S, Zhang G, Wanner A, Salathe M, Baier H, Sandhaus RA, Respir Med 2009 103 1532 1539 10.1016/j.rmed.2009.04.008 19464158
53. High dose intravenous AAT and plasma neutrophil derived fibrinogen fragments. Stolk J, Nieuwenhuizen W, Thorax 2005 60 84 85 15618590
54. Costs of chronic bronchitis and COPD. A one year follow-up study. Miravitlles M, Murio C, Guerrero T, Gisbert R, on behalf of the DAFNE study group, Chest 2003 123 784 791 10.1378/chest.123.3.784 12628879 (Pubitemid 36315494)
55. Lung function impairment, COPD hospitalisations and subsequent mortality. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ, Thorax 2011 66 585 590 10.1136/thx.2010.152876 21515553
56. Lung deposition of inhaled alpha-1-proteinase inhibitor in cystic fibrosis and alpha-1-antitrypsin deficiency. Brand P, Schulte M, Wencker M, Herpich CH, Klein G, Hanna K, et al. Eur Respir J 2009 34 354 360 10.1183/09031936.00118408 19251783
57. International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin Deficient Patients With Emphysema Alpha-1 Antitrypsin (AAT). 2010 ClinicalTrials.gov NCT01217671
58. Specific antibody response against the 23-valent pneumococcal vaccine in patients with alpha-1-antitrypsin deficiency with and without bronchiectasis. Miravitlles M, de Gracia J, Rodrigo MJ, Cruz MJ, Vendrell M, Vidal R, Morell F, Chest 1999 116 946 952 10.1378/chest.116.4.946 10531158 (Pubitemid 29491864)
59. Prevalence and impact of bronchiectasis in alpha-1 antitrypsin deficiency. Parr DG, Guest PG, Reynolds JH, Dowson LJ, Stockley RA, Am J Respir Crit Care Med 2007 176 1215 1221 10.1164/rccm.200703-489OC 17872489 (Pubitemid 350256475)
60. Alpha-1 antitrypsin serum levels in widespread bronchiectasis. El-Kassimi FA, Warsy AS, Uz-Zaman A, Pillai DK, Respir Med 1989 83 119 121 10.1016/S0954-6111(89)80225-2 2602595 (Pubitemid 19172825)
61. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. O'Brien C, Guest PJ, Hill SL, Stockley RA, Thorax 2000 55 635 642 10.1136/thorax.55.8.635 10899238 (Pubitemid 30468217)
62. Factors associated with bronchiectasis in chronic obstructive pulmonary disease patients. Martínez-Garcia MA, Soler-Cataluña JJ, Donat Y, Catalán S, Agramunt M, Ballestín J, et al. Chest 2011 140 1130 1137 10.1378/chest.10-1758 21546440
63. Bronchiectasis, exacerbation índices, and inflammation in chronic obstructive pulmonary disease. Patel IS, Vlahos I, Wilkinson TMA, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Am J Respir Crit Care Med 2004 170 400 407 10.1164/rccm.200305-648OC 15130905 (Pubitemid 39214614)
64. Standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency. American Thoracic Society/ European Respiratory Society Statement, Am J Respir Crit Care Med 2003 168 818 900 14522813
65. Perspectives for improving the evaluation and access of therapies for rare lung diseases in Europe. Luisetti M, Balfour-Lynn IM, Johnson S, Miravitlles M, Strange C, Trapnell B, van Bronswijk H, Vogelmeier C, Respir Med 2012 106 759 768 10.1016/j.rmed.2012.02.016 22414566
66. CT scan appearance, densitometry and health status in protease inhibitor SZ a1-antitrypsin deficiency. Holme J, Stockley RA, Chest 2009 136 1284 1290 10.1378/chest.09-0057 19892672
67. Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Soy D, de la Roza C, Lara B, Esquinas C, Torres A, Miravitlles M, Thorax 2006 61 1059 1064 10.1136/thx.2005.057943 16928711 (Pubitemid 44852024)